Fibrosis and disease progression in hepatitis C

Hepatology

Volumn 36, Issue 5 I, 2002, Pages s47-s56

  Marcellin, Patrick ^a   Asselah, Tarik ^a   Boyer, Nathalie ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE;

ACCURACY; ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; FATTY LIVER; FEMALE; FIBROGENESIS; GENDER; GENOTYPE; HEPATITIS C; HUMAN; IMMUNE DEFICIENCY; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; STELLATE CELL; VIRUS LOAD;

EID: 0036829652     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36993     Document Type: Conference Paper

References (63)

1. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001;21:351-372.
2. Martinez Hernandez A, Amenta PS. Morphology, localization and origin of the hepatic extracellular matrix. In: Zern MA, Reid LM eds. Extracellular Matrix, Chemistry, Biology and Pathobiology With Emphasis on the Liver. New-York: Dekker, 1993:201-254.
3. Lefkowitch JH, Schiff ER, Davis GL, Perillo RP, Lindsay K, Bodenheimer HC, Balart LA, et al. Pathological diagnosis of chronic hepatitis C. A multicenter comparative study with chronic hepatitis B. Gastroenterology 1993;104:595-603
4. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992;15:567-571.
5. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995;15:70-81.
6. Bedossa P. The cell origin of extracellualr matrix proteins. J Hepatol 1993;19:1-3.
7. Eng FJ, Friedman SL. Fibrogenesis I. New insights into hepatic stellate cell activation: The simple becomes complex. Am J Physiol 2000;279:G7-G11.
8. Guido M, Rugge M, Chemello L, Leandro G, Fattovich G, Giustina G, Cassaro M, et al. Liver stellate cells in chronic viral hepatitis: The effect of interferon therapy. J Hepatol 1996;24:301-307.
9. Bedossa P, Poynard T, Mathurin P, Lemaigre G, Chaput M. TGF-beta1 in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon. Gut 1993;34(Suppl 2):S146-S147.
10. Paradis V, Mathurin P, Laurent A, Charlote F, Vidaud M, Poynard T, Hoang C, et al. Histological features predictive of liver fibrosis in chronic hepatitis C infection. J Clin Pathol 1996;49:1-7.
11. Paradis V, Dargere D, Vidaud M, De Gouville AC, Huet S, Martinez V, Gauthier JM, et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999;30:968-976.
12. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numeral scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
13. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histologic grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
14. Bedossa P, Poynard T. The METAVIR cooperative study group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24:289-293.
15. Poynard T, Bedossa P, Opolon P for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.
16. Poynard T, Ratziu V, Charlotte F, Goodman Z, Mchutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-739.
17. Marcellin P, Akrémi R, Cazals D, Boyer N, Aupérin A, Vidaud D, Degott C. Genotype 1 is associated with a slower progression of fibrosis in untreated patients with mild chronic hepatitis C. J Hepatol 2001;34 (Suppl. 1):159. [abstract]
18. Ghany MG, Kleiner DE, Alter HJ, Doo E, Khokhar F, Park Y, Liang TJ, et al. Progression of fibrosis in early stages of chronic hepatitis C. Hepatology 2000;32:496A.
19. Alberti A, Boccato S, Ferrari A, Benvegnu L, Pontisso P, Noventa F, Gatta A. Outcome of initially mild chronic hepatitis C [abstract]. Hepatology 2001;34:225A.
20. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, et al. Long-term mortality after transfusion associated non-A non-B hepatitis. The National Heart, Lung and Blood Institute Study Group. N Engl J Med 1992;327:1906-1911.
21. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin Liver Dis 2000;20:17-35.
22. Tong MJ, El-Farra NS, Reijes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
23. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-1233.
24. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study. Hepatology 2000;32:91-96.
25. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-816.
26. Wiley TE, McCarthy M, Breidi L, Mc Carthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805-809.
27. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, Degott C, et al. Effect of alcohol consumption on serum hepaitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998;27:1717-1722.
28. Khan KN, Yatsuhashi H. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients. Alcohol Alcohol 2000;35:286-295.
29. Geissler M, Gesien A, Wands JR. Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core protein are reversed by genetic immunizations augmented with cytokine-expressing plasmids. J Immunol 1997;159:5107-5113.
30. Kim WH, Hong F, Jaruga B, Hu Z, Fan S, Liang TJ, Gao B. Additive activation of hepatic NF-kappaB by ethanol and hepatitis B protein X (HBX) or HCV core protein: Involvement of TNF-alpha receptor 1-independent and -dependent mechanisms. FASEB J 2001;15:2551-2553.
31. Oshita T, Hayashi N, Kasahara A, Hagiwara H, Mita E, Naito M, Katayama K, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994;20:1115-1120.
32. Haydon GH, Jarvis LM, Blair CS, Simmonds P, Harrison DJ, Simpson KJ, Hayes PC. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. Gut 1998;42:570-575.
33. Soto B, Sanchez-Quijano A, Rodrigo L, Leal M, Lissen E. HIV infection modifies the natural history of chronic parenterally acquired heptitis C with an unusually rapid progression to cirrhosis. A multicenter study on 547 patients. J Hepatol 1997;26:1-5.
34. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, Matheron S, et al. Influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study. Hepatology 2001;34:1193-1199.
35. Prieto M, Berenguer M, Rayon M, Cordoba J, Argüello L, Carrasco D, Garcia-Herola A, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. HEPATOLOGY 1999;29:250-256.
36. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, Cordoba J, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000;32:673-684.
37. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, Moya A, et al. Contribution of donor age to the recent decrease in patient survival among HVC-infected liver transplant recipients. Hepatology 2002;36:202-210.
38. Zeuzem S, Franka A, Lee JH, Herrmann G, Rüster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology 1996;24:1003-1009.
39. Martinot-Peignoux M, Marcellin P, Gournay J, Gabriel F, Courtois F, Branger M, Wild AM, et al. Detection and quantitation of serum hepatitis C virus (HCV) RNA by branched DNA amplification in anti-HCV positive blood donors. J Hepatol 1994;20:676-678.
40. Gervais A, Martinot M, Boyer N, Aupérin A, Le Breton V, Degott C, Valla D, et al. Quantitation of hepatic hepatitis C virus RNA with chronic hepatitis C, relationship with severity of disease, viral genotype and response to treatment. J Hepatol 2001;35:399-405.
41. Silini E, Bottellli R, Asti M, Bruno S, Candusso ME, Brambilla S, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A case control study. Gastroenterology 1996;111:199-205.
42. Marcellin P. Hepatitis C: The clinical spectrum of the disease. J Hepatol 1999;31:(suppl 1):9-16.
43. Pawlotsky JM, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A, Darthuy E, et al. Genetic complexity of the hypervariable region 1 (HVR 1) of hepatitis C virus. Influence on the characteristics of the infection and the response to alpha-interferon therapy in patients with chronic hepatitis C. J Med Virol 1998;54:256-264.
44. Asselah T, Martinot M, Cazals-Hatem D, Boyer N, Aupérin A, Le Breton V, Erlinger S, et al. Hypervariable region 1 quasispecies in hepatitis C virus gentotype 1b and 3 infected patients with normal and abnormal serum alanine aminotransferase levels. J Viral Hepat 2002;9:29-35.
45. Smith BC, Grove J, Guzail MA, Day CP, Daly AK, Burt AD, Bassendine MF, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-1699.
46. Adinolfi LE, Gambardella M, Andreana A, Tripodi M-F, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-1364.
47. Hwang SJ, Luo JC, Chu CW, Lai CR, Lu CL, Tsay SH, Wu JC, et al. Hepatic steatosis in chronic hepatitis C virus infection: Prevalence and clinical correlation. J Gastroenterol Hepatol 2001;21:190-195.
48. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-1219.
49. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed non-alcoholic fatty liver disease. Liver 2001;21:266-271.
50. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, et al P. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001;34:1000-1005.
51. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868-872.
52. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, Palmentieri B, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000;118:760-764.
53. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95:734-739.
54. Pohl A, Behling C, Olivier D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001;96:3142-3146.
55. Imbert-Bismut, F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, for the MULTIVIRC group. Biochemical markers of liver fibrossis in patients with hepatitis C virus infection: A prospective study. Lancet 2001;357:1069-1075.
56. Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: Relationship to liver histology. Hepatology 1994;20:780-787.
57. Guechot J, Poupon RE, Poupon R. Serum hyaluronan as a marker of liver fibrosis. J Hepatol 1995;22:103-106.
58. Gabrielli GB, Capra F, Casaril M, Squarzoni S, Tognella P, Dagradi R, De Maria E, et al. Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis. Clin Chim Acta 1997;265:21-31.
59. Neuman MG, Benhamou JP, Bourlière M, Ibrahim A, Malkiewicz I, Asselah T, Martinot-Peignoux M, et al. Serum TNF-α and TGF-β levels in chronic hepatitis C patients are modulated by therapy. Cytokine 2002;17:108-117.
60. Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, Masuzawara M, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 1997;26:574-583.
61. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-1340.
62. Baroni GS, Pastorelli A, Manzin A, Beneddi A, Marucci L, Solforosi L, Di Sario, et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver 1999;19:212-219.
63. Bedossa P, Paradis V, Lazure T. Hépatites chroniques virales. In: La Biopsie Hépatique en Pathologie non Tumorale du Foie. Groupe Metavir. Paris, France: Elsevier, 2000, p. 31.